1. The use of a parenteral composition containing an anti-virus amount of brecanavir or a pharmaceutically acceptable acid addition salt thereof and a carrier, without an additional agent having a positive effect on the metabolism and / or pharmacokinetics of the drug with respect to improving bioavailability, for the manufacture of a medicament for treating a subject, infected with HIV, where the composition should be administered by subcutaneous or intramuscular injection periodically at intervals ranging from Vuh weeks to one goda.2. The use according to claim 1, in which ritonavir is an additional agent having a positive effect on the metabolism and / or pharmacokinetics of the drug with respect to improving bioavailability. The use according to claim 1, wherein the parenteral composition is a solution containing an effective amount of brecanavir and an aqueous carrier. The use of claim 3, wherein a solubilizer or surfactant is added to said solution. The use according to any one of claims 1 to 4, in which the composition should be administered with an interval in the range from two weeks to one month. The use according to any one of claims 1 to 4, in which the composition should be administered with an interval in the range from one month to three months. The use according to any one of claims 1 to 4, in which the composition should be administered with an interval in the range from three months to six months. The use according to any one of claims 1 to 4, in which the composition should be administered once a month. The use according to any one of claims 1 to 4, in which the composition should be administered once every three months. The use according to claim 1, in which the plasma content is supported�1. Применение парентерального состава, содержащего эффективное против вируса количество бреканавира или его фармацевтически приемлемой аддитивной соли кислоты и носитель, без дополнительного агента, обладающего положительным эффектом на метаболизм и/или фармако
